Theravance Biopharma Inc.

Publicly traded biopharmaceutical companies have faced a rough year for fundraising in 2025 with the amount of money raised across all financing types down significantly from 2024 levels during the

The big respiratory players will be casting envious glances at the launch of Verona Pharma’s chronic obstructive pulmonary disorder (COPD) drug, Ohtuvayre, which is going from strength to strength. Th

Having delivering a submission for ensifentrine to the desks of US regulators, Verona Pharma plc is now putting in place a strategy designed to give its closely watched chronic obstructive pulmonary

Following the failure of its antibiotic ridinilazole in Clostridium difficile infection in December 2021, Summit Therapeutics plc executed a pivot from anti-infectives to oncology a year later whe